News & Updates

In children with newly diagnosed inflammatory bowel disease (IBD), overweight and obese status are not associated with worse disease activity at 1 year after diagnosis compared with normal weight, results of a study have shown.

The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.

In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.

People who consume sugar-sweetened beverages, rather than artificially sweetened beverages or natural juices, are at increased risk of developing inflammatory bowel disease, especially Crohn’s disease, as reported in a study.

First-line treatment with tumour necrosis factor-α (TNF-α) blockers is both safe and effective in children with inflammatory bowel disease (IBD), according to a recent study. Early drug initiation even cuts the likelihood of treatment failure and leads to fewer extraintestinal symptoms.

Coinfection with hepatitis B virus (HBV) among patients with tuberculosis (TB) appears to be 38-percent to 450-percent more prevalent than published estimates from the Polaris group of region-specific overall HBV prevalence, suggest the results of a meta-analysis.

Researchers at the Chinese University of Hong Kong (CUHK) have rolled out the city’s first territory-wide study of long COVID to inform multidisciplinary follow-up care for thousands of COVID-19 survivors. Participants are also invited to a second-phase 3-year prospective study of the impact of gut dysbiosis on long COVID symptoms and the potential role of gut microbiome modulation in treatment of long COVID.